The Drugs Controller General of India (DCI) on Thursday banned all charges except supply and processing costs on blood units.

DCGI has also asked the drug controller cum licensing authorities to direct all blood centres to adhere to the revised guidelines for recovery of processing..

*Manipal Academy of Higher Education's (MAHE)* 31^st Convocation concluded on 26^th November. It marked the end of an emotional and joyous four days during which..

*Manipal Academy of Higher Education (MAHE)*, an Institution of Eminence, deemed to be University, one of Indias leading research focused educational..

The Drug Controller General of India (DCGI) has suggested that a rule regulating the advertisement of ayush drugs should only be withdrawn after amendments to..

The Drug Controller General of India (DCGI) has advised doctors and healthcare professionals to educate their patients to discontinue the use of Digene gel - a..

Digene Gel, which is used as an antacid in many Indian homes, is now under the radar of the DGCI as an alert has been issued after the product's recall.

​Drugs Controller General of India (DCGI) has warned against the use of pholcodine-containing cold and cough drugs. The warning from the country's drug..

WHO warns of anaphylactic risks for those who took pholcodine cough syrups before anesthesia with NMBAs.

Cough syrup exporters will have to produce a certificate of analysis issued by a government laboratory before the product is exported, effective June 1, the..

Covovax can be administered to those who have already vaccinated with Covishield or Covaxin. The Drugs Controller General of India (DCGI) on January 16 had..

PLI scheme aims to give companies incentives on incremental sales from products manufactured in domestic units.

Covid-19 vaccine India: The Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for..

DCGI has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults.

Drugs Controller General of India (DCGI) Dr V G Somani said a statement issued by WHO in October in the wake of the deaths "was unfortunately amplified by the..

For individuals 18 years of age and older, the DCGI has authorised the use of Bharat Biotech's five arms heterologous booster, ANI reported.

Rutendo Kuwana from the WHO on October 13 had written to the DCGI seeking to know the progress with the investigation of the manufacturer of the four cough..

The body said it had shut production in the manufacturing units of the company days.

Haryana’s Health Minister Anil Vij said if samples failed to meet the standards, strict action will be taken against the company and its owners. India's drug..

Haryana’s Health Minister Anil Vij said if samples failed to meet the standards, strict action will be taken against the company and its owners. India's drug..

The vaccine development data will be submitted to peer-reviewed journals, "INCOVACC was evaluated to determine its impact on safety.

The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so..

Bharat Biotech's intranasal vaccine has been approved for primary immunization against Covid in adults for restricted use in emergency situation.

Earlier on June 4, DCGI approved Corbevax as a precaution dose for those aged 18 and above.

The Drug Controller General of India gave its nod to conduct clinical trials for BBIL's intranasal vaccine as a booster dose.

The Subject Expert Committee under India's drug regulator has found data submitted by Gennova Biopharmaceuticals "satisfactory".

The DCGI had approved Covovax for restricted emergency use in adults on December 28, 2021, and in 12-17 years age group on March 9, 2022.

The Drugs controller general of India (DCGI) is expected to give Emergency Use Authorisation to Gennova`s mRNA vaccine any time soon.

The Subject Expert Committee (SEC) in a meeting held on Friday recommended Emergency Use Authorisation (EUA) for India's first mRNA COVID-19 vaccine, sources..

The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India's first indigenously-developed..

 "The Subject Expert Committee of Drugs Controller General Of India (DCGI) has recommended Serum Institute of India`s (SII) vaccine Covovax for children in the..

An expert panel of India's central drug authority on Friday recommended granting emergency use authorisation to Serum Institute's Covovax for children aged 7 to..

The company will submit its data to the Drugs Controller General of India (DCGI) next month, said Dr Krishna Ella, Bharat Biotech chief.

CORBEVAX has become the first vaccine in India to get DCGI approval for COVID-19 booster dose. 

In April, DCGI had given emergency use authorisation (EUA) to Corbevax for children between 5 and 12 years.

Bharat Biotech has sought permission from India's drug regulator to conduct a phase 2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two..

The Drugs Controller General of India (DCGI) has given a restricted emergency use authorisation to Bharat Biotech's Covaxin for children aged 6-12 years, ANI..

The Drug Controller General of India (DCGI) on Tuesday granted emergency use approval to Covid-19 vaccines, Covaxin and Corbevax, for children below 12. Bharat..

The Drug Controller General of India (DCGI) has given a restricted emergency use approval for Bharat Biotech's Covid-19 vaccine, Covaxin, for children between..

DCGI has approved the emergency use authorisation for Bharat Biotech's Covaxin for children aged 6-12 years.

The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its Covid-19 vaccine, Covaxin,..